GLIOBLASTOMA

VB-111, is a targeted anti-cancer biologic agent that is positioned to potentially treat a wide range of solid tumors indications.

 

asp0052-vbl-57076-01-globe-logo-hires

 

Following successful Phase 2 study, VB-111 was advanced to a Phase 3 trial in rGBM.
GLOBE was a controlled, double-arm, open-label Phase 3 study designed to evaluate our therapeutic candidate VB-111 in combination with bevacizumab (also known as Avastin) in patients with recurrent glioblastoma. 

In March 2018, we announced top-line results from the GLOBE study, which showed that the study did not meet its pre-specified primary endpoint of overall survival (OS) or the secondary endpoint of progression-free survival (PFS). We are still performing analyses on the data from GLOBE study, which we intend to report later this year. 

We do not think that results of the particular GLOBE study that investigated VB-111 in combination with bevacizumab in rGBM, will necessarily have implications on the prospects for VB-111 in other tumor types, in different patients populations, or in different regimens.